1. Home
  2. JFB vs KPTI Comparison

JFB vs KPTI Comparison

Compare JFB & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JFB
  • KPTI
  • Stock Information
  • Founded
  • JFB 2014
  • KPTI 2008
  • Country
  • JFB United States
  • KPTI United States
  • Employees
  • JFB N/A
  • KPTI N/A
  • Industry
  • JFB
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • JFB
  • KPTI Health Care
  • Exchange
  • JFB NYSE
  • KPTI Nasdaq
  • Market Cap
  • JFB 37.3M
  • KPTI 33.6M
  • IPO Year
  • JFB 2025
  • KPTI 2013
  • Fundamental
  • Price
  • JFB $4.14
  • KPTI $6.02
  • Analyst Decision
  • JFB
  • KPTI Strong Buy
  • Analyst Count
  • JFB 0
  • KPTI 5
  • Target Price
  • JFB N/A
  • KPTI $61.00
  • AVG Volume (30 Days)
  • JFB 15.6K
  • KPTI 154.7K
  • Earning Date
  • JFB 01-01-0001
  • KPTI 05-07-2025
  • Dividend Yield
  • JFB N/A
  • KPTI N/A
  • EPS Growth
  • JFB N/A
  • KPTI N/A
  • EPS
  • JFB 0.02
  • KPTI N/A
  • Revenue
  • JFB $23,087,885.00
  • KPTI $145,237,000.00
  • Revenue This Year
  • JFB N/A
  • KPTI $4.87
  • Revenue Next Year
  • JFB N/A
  • KPTI $16.29
  • P/E Ratio
  • JFB $280.04
  • KPTI N/A
  • Revenue Growth
  • JFB N/A
  • KPTI N/A
  • 52 Week Low
  • JFB $3.39
  • KPTI $3.51
  • 52 Week High
  • JFB $4.87
  • KPTI $18.00
  • Technical
  • Relative Strength Index (RSI)
  • JFB N/A
  • KPTI 62.44
  • Support Level
  • JFB N/A
  • KPTI $3.83
  • Resistance Level
  • JFB N/A
  • KPTI $6.56
  • Average True Range (ATR)
  • JFB 0.00
  • KPTI 0.44
  • MACD
  • JFB 0.00
  • KPTI 0.40
  • Stochastic Oscillator
  • JFB 0.00
  • KPTI 91.47

About JFB JFB CONSTRUCTION HOLDINGS

JFB Construction Holdings is a commercial and residential real estate construction and development company. It is engaged in retail corporate buildouts, multifamily community developments and luxury residential homes, with a focus on fostering long-term relationships with clients, partners, and communities. The company operates in three distinct business segments: Commercial Construction, Residential Construction, and Real Estate Development. Key revenue is generated from Commercial Construction: This segment includes all activities related to the construction of commercial properties such as office buildings, retail spaces, and industrial facilities.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: